# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Tarcocimab clinical and non-clinical data highlight strong 6-month efficacy profile in diabetic retinopathy patients and contin...
UBS analyst Eliana Merle maintains Kodiak Sciences (NASDAQ:KOD) with a Neutral and raises the price target from $3 to $5.
Barclays analyst Gena Wang maintains Kodiak Sciences (NASDAQ:KOD) with a Underweight and raises the price target from $2 to $3.
Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-e...
U.S. stocks traded mixed this morning, with the Dow Jones index trading almost flat on Thursday. Following the market opening ...
Kodiak Sciences (NASDAQ:KOD) reported quarterly losses of $(1.13) per share which missed the analyst consensus estimate of $(0....